Which Biomanufacturing Strategies Have The Greatest Yield Potential?
Research and Markets has announced the addition of "Biomanufacturing Strategies: Market Drivers, Build-vs-Buy Decisions and Opportunities in Contract Relationship Management" to their offering.
The contract biomanufacturing market achieved a value of $2.5bn in 2006, with growth expected to continue at an annual rate of 0- 5% until at least 20. The proportion of biologics in new drug approvals has risen by over 30% during the last decade, and with the current pipeline containing more than 500 protein and 50 peptide developmental drugs, this trend is set to continue. The commercial success of over 350 approved biologics has prompted the biotechnology industry to accelerate discoveries in further protein-based therapeutics, placing greater emphasis upon the importance of biomanufacturing. Many biotechnology companies are faced with limited resources, and as large-scale manufacturing continues to intensify, deciding whether it should be internalised or outsourced to partners or CMO's is increasingly crucial in the development of a biotech firm.
Biomanufacturing Strategies is a new report published by Business Insights that examines the future direction of biomanufacturing through a detailed analysis of market drivers, restraints and trends. The production strategies and capacities of leading biopharma companies are assessed, and growth forecasts for microbial fermentations and mammalian cell culture are provided. This report will also detail the tactical balance required between a firm's potential manufacturing capability and overall corporate strategy, in addition to profiling other key factors that bear crucial importance to the ‘build vs buy' decision. Use this report to identify the key criteria involved in CMO selection, compare the expansion strategies and capacity shares of leading players and analyse the growth drivers shaping the future of biomanufacturing.
Some key findings from this report...
- The biotechnology industry is now consistently delivering clinically successful drugs for the treatment of human diseases, while the biopharmaceutical product pipeline is full and demand for new manufacturing capacity is growing steadily.
- The importance of contract manufacturing is increasing, as many large companies begin to scale back on production and focus on core competencies.
- The Contract Manufacturing Organisation (CMO) market will continue to grow at double-digit rates for the foreseeable future. Widespread benefits for large biotech firms as well as small to medium-scale pharma companies will drive this growth.
- Unequal distribution of biomanufacturing capacity may lead to supply shortages over the next few years, with the majority of current capacity being concentrated within fewer than 10 companies. However, substantial expansion in manufacturing capacity over the past five years is expected to be sufficient through 2007.
- Outsourcing to a CMO will drastically reduce financial risks for biotech companies by facilitating improved decision-making on both capital expenditure and capacity requirements.
Top five reasons to order your copy today
- Assess the outsourcing trends and manufacturing strategies that are crucial to biotech companies when facing ‘build vs buy' decisions.
- Discover which biomanufacturing strategies have the greatest yield potential and understand how disposable systems can impact upon cost and time improvements.
- Compare expansion strategies and evaluate the anticipated fluctuations in capacity share for leading CMO's, including Lonza Boehringer Ingelheim, Celltrion, DSM Biologics, Diosynth, Baxter Biopharma Solutions, Xcellerex, Cobra Biomanufacturing and Avecia.
- Understand the CMO selection criteria implemented by biotech companies when formulating outsourcing strategies and identify the key issues affecting the biomanufacturing market and industrial processes.
- Forecast available biomanufacturing capacity for both marketed products and those in clinical development.
For more information visit www.researchandmarkets.com/reports/c76311.
SOURCE: Business Insights